InvestorsHub Logo
Followers 296
Posts 31501
Boards Moderated 4
Alias Born 12/04/2008

Re: Stoltmann post# 346

Tuesday, 06/09/2020 4:45:58 PM

Tuesday, June 09, 2020 4:45:58 PM

Post# of 390
Yes it is very good for us Sativa Group is our vehicle to market and they have done well the last couple of years-will resume trading in August I guess that's a long time on an accquistion imo

Quarter 1 2020 Management Accounts Highlights

3 June 2020

Sativa Group Plc (AQSE: SATI), (or “Sativa” or “the Company” or “the Group”), the UK’s leading quoted CBD wellness and medicinal cannabis company, is pleased to announce its audited results from the year ended 31 December 2019, and draft unaudited Quarter 1 2020 interim management results.


Revenue increased by greater than five-fold from £0.26m to £1.45 million in the year to 31 December 2019, representing an increase of 190% on the annualised run rate of the revenue reported in H2 2018.
Gross profit margin improved from 42% to 52%, due to a decrease in the cost of CBD extract and production efficiencies, within market expectations.
The Group continues to expand its range of products, with the launch of the flagship Goodbody Botanicals brand, targeted at high-street pharmacies, grocers and independent pharmacies, and Goodbody Wellness, the premium health and beauty range.
The Tessellate Collective business was launched in Q2, opening up a new revenue stream as the direct selling channel.
Distribution partnership agreement signed with SHS Retail & Distribution a leader in distribution to high street grocers and pharmacies.
Sativa Cultivation & Extraction awarded a Home Office Controlled Drug licence, to fulfil its research partnership agreement with King’s College London.
Henry Lees-Buckley appointed as Chief Executive Officer in August. Henry was previously CEO of Uni-Select [TSX:UNS], a Canadian TSX quoted company.
Clive Page OBE, Professor of Pharmacology at King’s College London, appointed to Scientific Advisory Board.
PhytoVista Laboratories, increasingly recognised as a leading UK analytical laboratory for the testing of cannabinoids and terpenes, completed it’s 3,000th cumulative sample test in December, 90% of which was for external CBD and food manufacturers.
The Company completed a £1.38 million (before costs) share placement and subscription in December, the majority of which came from existing shareholders.

Full Results can be accessed from our Shareholder information Page

For further information please contact:

Henry Lees-Buckley
Chief Executive Officer
Sativa Group Plc
+44 (0) 20 7971 1255

Joseph Colliver
Chief Financial Officer
Sativa Group Plc
+44 (0) 20 7971 1255

M&A | Healthcare
Stillcanna to acquire UK based Sativa Group
Jun. 3, 2020 1:50 PM ET|About: Stillcanna Inc. (SCNNF)|By: Akanksha Bakshi, SA News Editor

Stillcanna (OTC:SCNNF) announces the acquisition of Sativa Group PLC, one of the United Kingdom's first medical cannabis companies.

The Offer is a share for share exchange offer at a ratio of ~0.33507 new Stillcanna shares in exchange for each share of Sativa; the exchange ratio attributes an implied value for the entire issued share capital of Sativa of ~£10.41M.

Stillcanna will continue to trade, on the CSE, OTC and FSE following completion, expected in August 2020.

Stillcanna has begun its Novel Food Application and has hired Global Regulatory Services of the UK, an award winning global consulting firm with a specialty in Novel Food applications.

Stillcanna has begun its agricultural initiatives in Europe to secure a steady availability of hemp biomass for the NEXUS extraction facility in Poland for 2020 and 2021.

Company has agreements with multiple European based hemp farmers to assure high CBD content EU compliant hemp biomass for 2020, and anticipates processing a minimum of 18,000 kilos of biomass in its Polish facility every month but could double that amount should the market demand be there.

The belief in a supernatural source of evil is not necessary. Men alone are quite capable of every wickedness.”

Joseph Conrad